Alnylam Pharmaceuticals / 675 West Kendall
Cambridge, MADOWNLOAD PROJECT PROFILE
About the project
In 2016 Alnylam signed the lease on 675 West Kendall, Cambridge consolidating their Kendall Square Campus, which includes 300 Third Street and 101 Main Street, and began creating their new headquarters.
Hereva Consultants provided project management services to Alnylam which consisted of the renovation of the existing building, including infrastructure, lab and office space at 675 West Kendall. This site allowed for Alnylam’s expansion, and for the realignment of office and lab space in their real estate portfolio. Our work began with the initial master planning effort and continued with project management support for the design, construction and move-in phases of the project. Construction began in May 2018 and is expected to be completed by the end of 2019.
Key challenges for this project was that direction changed several times during the design process. It was determined that the project would minimize renovation and consolidate all lab functions upon completion. In addition, the team had to execute a major base building HVAC upgrade which required coordination with the building landlord. Also, Alnylam is a chemistry intensive organization, and had extensive handling and storage requirements. For the ACF/Vivarium, cGMP processes were followed.
About the client
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi) therapeutics for genetically defined diseases. Alnylam is leading the translation of RNAi as a new class of innovative medicines for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.